Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis

Red de Terapia Celular20 enrolled

Overview

The purpose of this study is to evaluate the safety of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis by a prospective, single-center, randomized, parallel, double-blind, placebo-controlled phase I clinical trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Interventions

MNC (Mononuclear cells)BIOLOGICAL

The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point. For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device.

SalineOTHER

The placebo, 2ml of saline, will be infused like in the experimental arm.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of definite or probable ALS according to the criteria established by the World Federation of Neurology * Patient that provides reasonable assurance of adherence to protocol. * Neurophysiological data confirming affectation of lower motor neurons in the lumbar region. * Assessment of motor deficits in dorsiflexion of both feet (4 or 5 points on the MRC scale) * The patient must fulfill all inclusion criteria. Exclusion Criteria: * Diabetes Mellitus. * Other diseases that may present with polyneuropathy. * Previous history of stroke. * Prior Pathology of the peripheral nervous system affecting one or both lower limbs with or without clinically evident neurological sequelae. * Pregnant or breastfeeding patients active. * Patients physiologically capable of becoming pregnant, unless they are using reliable contraception. * Patients with cardiac disease, renal, hepatic, systemic, immune that may influence patient survival during the test. * Positive serology for hepatitis B, hepatitis C or HIV. * Clinical and anesthesiologic Criteria, contraindicating either sedation or extraction of MO (Altered coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, altered skin puncture site, etc.) * Included in other clinical trials in the last 6 months.

Locations (1)

Clinical Universitary Hospital Virgen de la Arrixaca

El Palmar, Murcia, Spain

Outcomes

Primary Outcomes

Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells in patients with Amyotrophic Lateral Sclerosis.

Time frame: 24 months from baseline

Secondary Outcomes

Estimated number of motor units (MUNE)

Several techniques for estimating the MUNE, all based on the relationship between the amplitude or area of compound muscle action potential (CMAP) and amplitude or area corresponding to a single motor unit response. The differences between the techniques are due to the different ways of estimating the amplitude of the responses for individual motor units. The study will use two techniques: Incremental Technique: The unitary amplitude (or area) of individual motor units are calculated from the responses to increasing intensities stimuli near of intensity threshold (Dantes and McComas, 1991) Statistical technique: The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity (Daube, 2006)

Time frame: 24 months from baseline

Compound muscle action potential (CMAP)

CMAP is registered after supramaximal stimulation intensity (0.1-0.2 ms pulses at 1 Hz) of the common peroneal nerve at the level of the head of the fibula. The electrical stimulus is placed in a fixed position during the entire registration process. CMAP will be recorded simultaneously in 5 positions along longitudinally oriented TA muscle. To determine these 5 positions bony landmarks that are reproducible between members and between different patients will be used.

Time frame: 24 months from baseline

Fiber density (FD)

Quantifies the average number of muscle fibers per motor unit. It is obtained from single fiber recordings made with electrodes. The average number of motor unit potentials is calculated in 20 different positions in the muscle.

Time frame: 24 months from baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.